The National Institute for Health Research (NIHR) in the UK has given special status to a study from Danish biotech company Union Therapeutics, according to a press release from the company.
Union Therapeutics' Protect-V trial tests the firm's niclosamide nasal spray on patients with kidney diseases having Covid-19.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.